Teva Statement Regarding the European Commission Decision; Company to be Objected | 31.10.24

• Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested and factually unsupported
• The company plans to appeal the outcome and is fully prepared to defend itself.
• Teva has supported the MS community since 1996 and will not hesitate to provide access to this important standard of care treatment.
• Teva operates all of our external experts to the highest ethical standards and does so in a highly regulated environment

TEL AVIV, Israel, October 31, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) answers the question: European Decision Following an investigation into the company’s practices regarding COPAXONE^® – standard of care treatment for multiple sclerosis – and a declaration of intention to appeal the decision and fine imposed.

The company is deeply disappointed by this decision and has been cooperating intensively with the EC since 2019. Teva disagrees with legal theories that the Commission believes are untested and unsupported by facts. The company will defend its position vigorously on appeal and is well prepared financially to mount a defense.

Teva conducts its business legally and ethically and has been a strong partner of Europe, its patients, its economy and its healthcare systems. This wrong decision will not deter Teva from its unwavering support for patients living with MS and their families.

Media Contact Information:

Kelley Dougherty (973) 832-2810

Eden Klein +972 (3) 906 2645